Skip to main content
Caplight Logo









Ymmunobio

Ymmunobio

Private
RiehenHealthcare & Life Scienceshttps://ymmunobio.com/

Last Round

Grant

Jan 23, 2025

Total Funding Raised

$1.93M

Company Overview

Ymmunobio is a drug discovery company developing first-in-class antibody-based therapies for solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

antibody-drug conjugateADCNPTXR targetsolid tumor therapycancer immunotherapynovel tumor targetfirst-in-class therapeuticsprecision oncologypreclinical biotechT-cell engagerradiopharmaceuticalsCAR-T therapyvirtual biotechliquid biopsy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ymmunobio Comparables

Compare Ymmunobio with similar companies based on industry and business-model similarity.

Ymmunobio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Gilead Sciences
81%
Taiho Pharmaceutical Co., Ltd.
77%
Sotio
77%

Ymmunobio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJan 23, 2025
SeedNov 13, 2023

Key People

Founding team and executive leadership

Peter Schiemann

CEO Chairman Of The Board

Executive Team

Christian Germa

Chief Financial Officer

Executive Team

Martin E. Zuzulo

Chief Operating Officer

Executive Team

Ymmunobio Investors

Notable investors and investment history

Ymmunobio investors
InvestorRounds
OKG CapitalSeed
InnosuisseGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 23, 2025

    $525K grant received from Innosuisse.

  • Nov 13, 2023

    $1.4M round led by OKG Capital

Ymmunobio Filings

Explore SEC and related filing metadata, where available.

Ymmunobio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Ymmunobio's valuation, stock price, and market status.

Is Ymmunobio a public or private company?

Ymmunobio is a private company.

What is the current stock price of Ymmunobio?

Ymmunobio is a private company with no public stock price. No recent secondary market data is available.

How much is Ymmunobio worth (valuation)?

Valuation information for Ymmunobio is not publicly available.

Can I buy Ymmunobio stock?

Ymmunobio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Ymmunobio's last funding round?

Ymmunobio's most recent funding round was Grant on January 23, 2025.

Who are the main investors in Ymmunobio?

Key investors in Ymmunobio include OKG Capital, Innosuisse.

Will Ymmunobio IPO soon?

No public IPO plans have been announced for Ymmunobio.

How can I track Ymmunobio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ymmunobio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRiehen
Employee Range5
Year Founded2021
Last FundingJan 23, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?